Prognostic significance of tumor infiltrating lymphocytes in melanoma

American Surgeon

Volumn 77, Issue 2, 2011, Pages 188-192

  Burton, Alison L ^a   Roach, Brent A ^a   Mays, Michael P ^a   Chen, Andrea F ^a   Ginter, Brooke A R ^a   Vierling, Abbey M ^a   Scoggins, Charles R ^a   Martin, Robert C G ^a   Stromberg, Arnold J ^b   Hagendoorn, Lee ^c   McMasters, Kelly M ^a  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c Advertek Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DISEASE FREE SURVIVAL; FEMALE; HUMAN; KAPLAN MEIER METHOD; LOCAL EXCISION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PROGNOSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SENTINEL LYMPH NODE BIOPSY; THICKNESS; TUMOR ASSOCIATED LEUKOCYTE; ULCER; UNIVARIATE ANALYSIS;

ADULT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MELANOMA; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROSPECTIVE STUDIES; SKIN NEOPLASMS;

EID: 79952428550     PISSN: 00031348     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001;19:3622-34. (Pubitemid 32786275)
2. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970;172:902-8.
3. Elder DE, Guerry D IV, VanHorn M, et al. The role of lymph node dissection for clinical stage I malignant melanoma of intermediate thickness (1.51-3.99 mm). Cancer 1985;56:413-8. (Pubitemid 15031668)
4. Clark WH, Elder DE, Guerry D IV, et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 1989;81:1893-904. (Pubitemid 20026075)
5. Clemente CG, Mihm MC Jr, Bufalino R, et al. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996;77:1303-10. (Pubitemid 26102328)
6. Tuthill RJ, Unger JM, Liu PY, et al. Risk assessment in localized primary cutaneous melanoma: A Southwest Oncology Group study evaluating nine factors and a test of the Clark logistic regression prediction model. Am J Clin Pathol 2002;118:504-11. (Pubitemid 44698506)
7. Day CL Jr, Sober AJ, Kopf AW, et al. A prognostic model for clinical stage I melanoma of the lower extremity: location on foot as independent risk factor for recurrent disease. Surgery 1981;89:599-603. (Pubitemid 11040418)
8. Taylor RC, Patel A, Panageas KS, et al. Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma. J Clin Oncol 2007;25:869-75. (Pubitemid 350002888)
9. Larsen TE, Grude TH. A retrospective histological study of 669 cases of primary cutaneous malignant melanoma in clinical stage I. 3. The relation between the tumour-associated lymphocyte infiltration and age and sex, tumour cell type, pigmentation, cellular atypia, mitotic count, depth of invasion, ulceration, tumour type and prognosis. Acta Pathol Microbiol Scand 1978;86A:523-30.
10. Barnhill RL, Fine JA, Roush GC, et al. Predicting five-year outcome for patients with cutaneous melanoma in a population-based study. Cancer 1996;78:427-32. (Pubitemid 26250527)
11. Thorn M, Ponten F, Bergstrom R, et al. Clinical and histopathologic predictors of survival in patients with malignant melanoma: A population based study in Sweden. J Natl Cancer Inst 1994;86:761-9. (Pubitemid 24152891)
12. McMasters KM, Reintgen DS, Ross MI, et al. Sentinel lymph node biopsy for melanoma: how many radioactive nodes should be removed. Ann Surg Oncol 2001;8:192-7. (Pubitemid 32294797)
13. Gershenwald JE, Thompson W, Mansfield PF, et al. Multiinstitutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999;17:976-83. (Pubitemid 29109331)
14. Kruper L, Botbyl B, Czerniecki B, et al. Sentinel lymph node status in stage II/III melanoma. J Clin Oncol 2005;23:710S.
15. Mandalà M, Imberti GL, Piazzalunga D, et al. Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I-II AJCC skin melanoma: outcome analysis from a single-institution prospectively collected database. Eur J Cancer 2009;45:2537-45.
16. Payette MJ, Katz M III, Grant-Kels JM. Melanoma prognostic factors found in the dermatopathology report. Clin Dermatol 2009;27:53-74.
17. Piras F, Colombari R, Minerba L, et al. The predictive value of CD8, CD4, CD68, and human leukocyte antigen-D-related cells in the prognosis of cutaneous malignant melanoma with vertical growth phase. Cancer 2005;104:1246-54. (Pubitemid 41278960)
18. van Houdt IS, Sluijter BJ, Moesbergen LM, et al. Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T-lymphocytes and preserved MHC class I antigen expression. Int J Cancer 2008;123:609-15. (Pubitemid 351898419)